Literature DB >> 9672234

Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease.

F T Valentine1, A Paolino, A Saito, R S Holzman.   

Abstract

Lymphocyte-proliferative responses (LPRs) to HIV antigens are absent or of low magnitude in the majority of HIV-infected individuals, even early in the disease. However, lymphocytes from 2% to 3% of individuals proliferate very strongly to HIV Env or Gag antigens, and these individuals remain well clinically, without antiretroviral therapy. In established HIV infection, suppression of HIV-replication with potent antiretroviral therapy does not result in the development of strong LPRs to HIV antigens. Large LPRs to HIV antigens can be induced by HIV vaccines in patients with established infection, even though they were not formed in response to infection. Studies must be designed to determine whether large LPRs induced by vaccines administered in conjunction with potent antiretroviral therapy are associated with long-term control of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672234

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

Authors:  A C McNeil; W L Shupert; C A Iyasere; C W Hallahan; J A Mican; R T Davey; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Malaria infection induces rapid elevation of the soluble Fas ligand level in serum and subsequent T lymphocytopenia: possible factors responsible for the differences in susceptibility of two species of Macaca monkeys to Plasmodium coatneyi infection.

Authors:  J Matsumoto; S Kawai; K Terao; M Kirinoki; Y Yasutomi; M Aikawa; H Matsuda
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

4.  Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.

Authors:  Said Aboud; Charlotta Nilsson; Katarina Karlén; Mary Marovich; Britta Wahren; Eric Sandström; Hans Gaines; Gunnel Biberfeld; Karina Godoy-Ramirez
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

5.  Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2.

Authors:  Christiana Iyasere; John C Tilton; Alison J Johnson; Souheil Younes; Bader Yassine-Diab; Rafick-Pierre Sekaly; William W Kwok; Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; Claire W Hallahan; Richard T Davey; Mark Dybul; Susan Vogel; Julia Metcalf; Mark Connors
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection.

Authors:  Stephen A. Migueles; Mark Connors
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

7.  HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.

Authors:  Souheil-Antoine Younes; Bader Yassine-Diab; Alain R Dumont; Mohamed-Rachid Boulassel; Zvi Grossman; Jean-Pierre Routy; Rafick-Pierre Sekaly
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

8.  A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.

Authors:  Gareth Ad Hardy; Nesrina Imami; Mark R Nelson; Ann K Sullivan; Ron Moss; Marlén Mi Aasa-Chapman; Brian Gazzard; Frances M Gotch
Journal:  J Immune Based Ther Vaccines       Date:  2007-04-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.